ArticlePloS one2008
An information-theoretic analysis of genetics, gender and age in cancer patients.
Article in PloS one, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 22 citations in OpenAlex.
- Common genetic variants in the TP53 pathway and their impact on cancer.Journal of molecular cell biology · 2019Review
- Decoding cancer heterogeneity: studying patient-specific signaling signatures towards personalized cancer therapy.Theranostics · 2019Article
- Personalized disease signatures through information-theoretic compaction of big cancer data.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- The Role of MDM2 Amplification and Overexpression in Tumorigenesis.Cold Spring Harbor perspectives in medicine · 2016Review
- The MDM2 285G-309G haplotype is associated with an earlier age of tumour onset in patients with Li-Fraumeni syndrome.Familial cancer · 2014Article
- Translational approaches targeting the p53 pathway for anti-cancer therapy.British journal of pharmacology · 2012Review
- Single-nucleotide polymorphisms in the p53 signaling pathway.Cold Spring Harbor perspectives in biology · 2010Review
- Association of MDM2 SNP309, age of onset, and gender in cutaneous melanoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2009Article
- p53 polymorphisms: cancer implications.Nature reviews. Cancer · 2009Review
- Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?Molecular cancer research : MCR · 2009Review
- Expression of a mutant p53 results in an age-related demographic shift in spontaneous lung tumor formation in transgenic mice.PloS one · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 8 institutions in 4 countries.
Funding
Abstract
Germline genetics, gender and hormonal-signaling pathways are all well described modifiers of cancer risk and progression. Although an improved understanding of how germline genetic variants interact with other cancer risk factors may allow better prevention and treatment of human cancer, measuring and quantifying these interactions is challenging. In other areas of research, Information Theory has been used to quantitatively describe similar multivariate interactions. We implemented a novel information-theoretic analysis to measure the joint effect of a high frequency germline genetic variant of the p53 tumor suppressor pathway (MDM2 SNP309 T/G) and gender on clinical cancer phenotypes. This analysis quantitatively describes synergistic interactions among gender, the MDM2 SNP309 locus, and the age of onset of tumorigenesis in p53 mutation carriers. These results offer a molecular and genetic basis for the observed sexual dimorphism of cancer risk in p53 mutation carriers and a model is proposed that suggests a novel cancer prevention strategy for p53 mutation carriers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.